Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

International Journal of Clinical Practice

Volumn 62, Issue 11, 2008, Pages 1693-1702

  Francois C ^a   Montgomery, S A ^b   Despiegel, N ^a   Aballea S ^c   Roiz J ^c   Auquier, P ^d  

^a Lundbeck   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c i3 Innovus   (United Kingdom)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO;

ARTICLE; CALCULATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG DOSE INCREASE; HEALTH CARE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SHORT FORM 36; SOCIAL PHOBIA; THERAPY EFFECT; UNITED KINGDOM;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CITALOPRAM; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 54049086574     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01879.x     Document Type: Article

References (37)

1. Sareen L, Stein M. A review of the epidemiology and approaches to the treatment of social anxiety disorder. Drugs 2000 59 : 497 509.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn, Text Revision (DSM-IV-TR). Arlington, VA : American Psychiatric Association, 2000.
3. Stein MB. An epidemiologic perspective on social anxiety disorder. J Clin Psychiatry 2006 67 (Suppl. 12 3 8.
4. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998 155 : 613 9.
5. Grant BF, Hasin DS, Blanco C et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 2005 66 : 1351 61.
6. Culpepper L. Social anxiety disorder in the primary care setting. J Clin Psychiatry 2006 67 (Suppl. 12 31 7.
7. Simon NM, Otto MW, Korbly NB, Peters PM, Nicolaou DC, Pollack MH. Quality of life in social anxiety disorder compared with panic disorder and the general population. Psychiatr Serv 2002 53 : 714 8.
8. Patel A, Knapp M, Henderson J, Baldwin D. The economic consequences of social phobia. J Affect Disord 2002 68 : 221 33.
9. Katzelnick DJ, Kobak KA, DeLeire T et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry 2001 158 : 1999 2007.
10. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998 280 : 708 13.
11. Van Ameringen MA, Lane RM, Walker JR et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001 158 : 275 81.
12. Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001 179 : 23 30.
13. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994 115 : 128 34.
14. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999 156 : 756 60.
15. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002 59 : 1111 8.
16. Walker JR, Van Ameringen MA, Swinson R et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000 20 : 636 44.
17. Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 2006 20 : 763 90.
18. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 2008 8 : 235 57.
19. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005 66 : 1270 8.
20. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery, 2nd revised edn. Chevy Chase, MD : National Institute of Mental Health [12-1-12-6], 1970.
21. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
22. Ware JE. SF-36 Physical and Mental Health Summary Scales: a User's Manual. Boston, MA : The Health Institute, New England Medical Center, 1994.
23. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000 17 : 13 35.
24. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 92.
25. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004 42 : 851 9.
26. Office for National Statistics. Annual Survey of Hours and Earnings, 2006. http://www.statistics.gov.uk (accessed 12 August 2008).
27. Lepine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 2002 63 (Suppl. 14 4 8.
28. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. CMAJ 1992 147 : 878 83.
29. Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005 8 : 10 23.
30. National Institute of Health and Clinical Excellence. Clinical Guideline 22. Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care, 2004 December. http://www.nice.org.uk/CG022NICEguideline (accessed 22 July 2007).
31. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004 13 : 873 84.
32. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005 14 : 1169 89.
33. Stein MB, Roy-Byrne PP, Craske MG et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005 43 : 1164 70.
34. Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev 2007 27 : 572 81.
35. British National Formulary. http://www.bnf.org/bnf/ (accessed 12 August 2008).
36. Curtis L, Netten A. Unit Costs of Health and Social Care. Kent : University of Kent, 2006.
37. Department of Health. NHS Reference Costs, 2006. http://www.dh.gov.uk (accessed 3 May 2007).